Essential Hypertension
Conditions
Keywords
hypertension, ramipril, blood pressure, artery stiffness, BNP, CRP
Brief summary
The purpose of this study is to assess which drug is more effective of Ramiprin®(ramipril) and Tritace®(ramipril) in the Treatment of Essential Hypertension
Interventions
DRUGRamipril
Sponsors
Pacific Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* mild and moderate essential hypertension (90mmHg≤DBP≤110mmHg)
Exclusion criteria
* 180mmHg≤SBP * If differences greater than 20mmHg for SBP and 10mmHg for DBP between both arms are present on 3 consecutive readings * If differences greater than 20mmHg for SBP and 10mmHg for DBP are present on 3 consecutive readings * impaired hepatic function * imapaired renal function * angioedema * aortic valvular stenosis or obstrcutive ejection disorder * primary hyperaldosteronism * renal transplantation, bilateral renal artery stenosis or unilateral stenosis in a single kidney, hemodialysis * severe respiratory disease * congestive heart failure( New York Association functional class Ⅲ or Ⅳ) * malignant hypertension * labile angina pectoris or myocardial infarction in the last 3 months before study entry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of DBP(diastolic blood pressure) | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of patients with Dcrease of BP(blood pressure) | — |
| Percentage of patients with a Normalization of BP(blood pressure) | — |
| Artery stiffness(chang of pulse wave velocity) | — |
| Reduction of SBP(systolic blood pressure) | — |
| Change of BNP | — |
| Change of CRP | — |
| Left ventricular diastolic function | — |
Countries
South Korea
Outcome results
None listed